Maze Therapeutics Files 8-K: Material Agreement, Equity Sales

TL;DR

Maze Therapeutics signed a big deal and sold some stock.

AI Summary

On September 10, 2025, Maze Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. Financial statements and exhibits were filed as part of this report.

Why It Matters

This 8-K filing indicates significant corporate activity for Maze Therapeutics, including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

• Maze Therapeutics, Inc. (company) — Registrant
• September 10, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-42490 (commission_file_number) — SEC File Number
• 171 Oyster Point Blvd., Suite 300 (address) — Principal Executive Offices
• South San Francisco, California (location) — City and State of Principal Executive Offices
• 94080 (zip_code) — Zip Code of Principal Executive Offices
• 650 850-5070 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock - par value $0.001 per share MAZE The Nasdaq Stock Mar
• $16.25 — Common Stock "), at a purchase price of $16.25 per share and (ii) in lieu of shares of
• $16.249 — " Securities ") at a purchase price of $16.249 per Pre-Funded Warrant. Each Pre-Funded
• $150.0 m — the Private Placement of approximately $150.0 million, before deducting placement agent

Filing Documents

• d90404d8k.htm (8-K) — 40KB
• d90404dex41.htm (EX-4.1) — 79KB
• d90404dex101.htm (EX-10.1) — 176KB
• d90404dex102.htm (EX-10.2) — 100KB
• d90404dex991.htm (EX-99.1) — 11KB
• d90404dex992.htm (EX-99.2) — 22KB
• g90404g0911100048877.jpg (GRAPHIC) — 3KB
• g90404g0911100824748.jpg (GRAPHIC) — 3KB
• 0001193125-25-200760.txt ( ) — 672KB
• maze-20250910.xsd (EX-101.SCH) — 3KB
• maze-20250910_lab.xml (EX-101.LAB) — 18KB
• maze-20250910_pre.xml (EX-101.PRE) — 11KB
• d90404d8k_htm.xml (XML) — 4KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement . Securities Purchase Agreement On September 10, 2025, Maze Therapeutics, Inc., a Delaware corporation (the " Company "), entered into a securities purchase agreement (the " Securities Purchase Agreement ") with certain institutional and accredited investors (the " Investors "), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the " Private Placement ") an aggregate of (i) 4,000,002 shares (the " Shares ") of the Company's common stock, par value $0.001 per share (the " Common Stock "), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the " Pre-Funded Warrants ") to purchase up to an aggregate of 5,231,090 shares of Common Stock (the " Warrant Shares " and, together with the Shares and the Pre-Funded Warrants, the " Securities ") at a purchase price of $16.249 per Pre-Funded Warrant. Each Pre-Funded Warrant has an exercise price of $0.001 per Warrant Share. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. The Private Placement is anticipated to close on or about September 12, 2025, subject to the satisfaction of customary closing conditions. The Company anticipates receiving gross proceeds from the Private Placement of approximately $150.0 million, before deducting placement agent fees and other expenses. The Company intends to use the proceeds from the private placement, together with its existing cash, cash equivalents and short-term investments, to advance the development of MZE829 in patients with APOL1-mediated kidney disease, initiate Phase 2 clinical trials of MZE782 in both phenylketonuria and chronic kidney disease, continue progress on research and discovery programs, further the development of its Compass platform, and for working capital and other general corporate purposes. The Pre-Funded Warrants to be issued in the

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities . The information contained above under Item 1.01, to the extent required by Item 3.02 of Form 8-K, is hereby incorporated by reference herein. Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Securities was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the " Securities Act ") and corresponding provisions of state securities or "blue sky" laws. The Securities have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of the Securities did not involve a public offering and was made without general solicitation or general advertising. The Investors represented that they are accredited investors, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that they are acquiring the Securities for investment purposes only and not with a view to any resale, distribution or other disposition of the Securities in violation of the U.S. federal securities laws. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure . On September 11, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on September 11, 2025, the Company issued a press release announcing results from its Phase 1 trial of MZE782. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K. The information furnished in this Item 7.01, including Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Current Report on Form 8-K and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the closing of the Private Placement, registration of the securities being issued and sold in the Private Placement, the Company's use of the proceeds from the Private Placement, statements concerning the Company's future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat CKD, PKU or other indications, the planned timing of the Company's clinical trials, data results and further development of MZE829, MZE782 and other therapeutics candidates, and the ability to drive financial results and stockholder value. In addition, when or if used in this Current Report on Form 8-K, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of factors, including risks and uncertaintie

01 . Financial Statements and Exhibits

Item 9.01 . Financial Statements and Exhibits . (d) Exhibits: Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1* Form of Securities Purchase Agreement. 10.2 Form of Registration Rights Agreement. 99.1 Press Release issued by the Company announcing the Private Placement, dated September 11, 2025. 99.2 Press Release issued by the Company announcing MZE782 data, dated September 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2025 By: /s/ Courtney Phillips Courtney Phillips General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR